The [134Ce]Ce-PSMA-617 groups demonstrated improvement in tumor volumes and overall survival (Fig. 6B), and the group receiving the higher dose, 111 MBq, showed prolonged survival in comparison with the 37-MBq and saline control groups. This evidence concerns the gene FOLH1 and neoplasm.